2025 India Antibody Drug Conjugates Contract Manufacturing Revenue Opportunities Report
Description
The 2025 India Antibody Drug Conjugates Contract Manufacturing Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Drug Conjugates Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Antibody Drug Conjugates (ADC) contract manufacturing market in India are Lonza Group, WuXi Biologics, Catalent, and Piramal Pharma Limited. These firms dominate the market with advanced biopharmaceutical manufacturing capabilities, offering comprehensive ADC services from antibody development to conjugation and fill-finish operations. Lonza Group and WuXi Biologics are recognized globally for their end-to-end ADC production platforms, including upstream cell culture, payload-linker synthesis, and bioconjugation technologies. Catalent provides integrated services with a focus on scalable clinical to commercial ADC manufacturing. Piramal Pharma Solutions recently expanded its ADC production capacity by 70-80%, strengthening its presence in the Indian and global market.
India’s ADC contract manufacturing market is driven by rising oncology drug demand, government support for biopharma innovation, and cost-effective manufacturing facilities staffed by skilled professionals. Strategic collaborations between domestic firms and global biopharma companies enhance technology transfer and innovation in conjugation and linker chemistry. The market growth is supported by GMP-compliant facilities, increasing investments in biologics, and a projected CAGR of around 13.3% through 2030. These companies leverage digital technologies, continuous manufacturing, and advanced analytics to ensure quality and accelerate ADC development timelines, positioning India as an emerging hub within the Asia-Pacific ADC manufacturing landscape.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Drug Conjugates Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Antibody Drug Conjugates (ADC) contract manufacturing market in India are Lonza Group, WuXi Biologics, Catalent, and Piramal Pharma Limited. These firms dominate the market with advanced biopharmaceutical manufacturing capabilities, offering comprehensive ADC services from antibody development to conjugation and fill-finish operations. Lonza Group and WuXi Biologics are recognized globally for their end-to-end ADC production platforms, including upstream cell culture, payload-linker synthesis, and bioconjugation technologies. Catalent provides integrated services with a focus on scalable clinical to commercial ADC manufacturing. Piramal Pharma Solutions recently expanded its ADC production capacity by 70-80%, strengthening its presence in the Indian and global market.
India’s ADC contract manufacturing market is driven by rising oncology drug demand, government support for biopharma innovation, and cost-effective manufacturing facilities staffed by skilled professionals. Strategic collaborations between domestic firms and global biopharma companies enhance technology transfer and innovation in conjugation and linker chemistry. The market growth is supported by GMP-compliant facilities, increasing investments in biologics, and a projected CAGR of around 13.3% through 2030. These companies leverage digital technologies, continuous manufacturing, and advanced analytics to ensure quality and accelerate ADC development timelines, positioning India as an emerging hub within the Asia-Pacific ADC manufacturing landscape.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
